Emerging clinical and therapeutic applications of Nigella sativa in gastroenterology.
Nigella sativa (N. sativa) decreases DNA damage and thereby prevents initiation of carcinogenesis in colonic tissue secondary to exposure to toxic agents such as azoxymethane. N. sativa is of immense therapeutic benefit in diabetic individuals and those with glucose intolerance as it accentuates glucose-induced secretion of insulin besides having a negative impact on glucose absorption from the intestinal mucosa. N. sativa administration protects hepatic tissue from deleterious effects of toxic metals such as lead, and attenuates hepatic lipid peroxidation following exposure to chemicals such as carbon tetrachloride.
Shailendra
S
Kapoor
D003920:Diabetes Mellitus / Q000188:drug therapy; D005762:Gastroenterology; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D031881:Nigella sativa / Q000737:chemistry*; D008517:Phytotherapy; D028321:Plant Preparations / Q000627:therapeutic use*
D005765:Gastrointestinal Agents; D028321:Plant Preparations